Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Vita Group expands skincare offering by acquiring Artisan clinic in Brisbane

2018-05-02 proactiveinvestors.com.au
Vita Group Limited (ASX:VTG) has expanded its non-invasive medical aesthetics (NIMA) portfolio by acquiring Artisan Cosmetic & Rejuvenation Clinic, located in Fortitude Valley, Brisbane.
VTG TLS

11
EU mergers and takeovers (April 3)

2018-04-03 reuters
BRUSSELS, April 3 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
KYGA MQBKY 500228 LNVGY UTX MCQEF KRYAF LKQ 0992 COL BGC JSWSTEEL VTG LNVGF KRYAY MQG

10
EU mergers and takeovers (March 26)

2018-03-26 reuters
BRUSSELS, March 26 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
KYGA MQBKY 500228 LNVGY UTX MCQEF KRYAF LKQ 0992 COL JSWSTEEL VTG LNVGF WYN KRYAY MQG

10
EU mergers and takeovers (March 23)

2018-03-23 reuters
BRUSSELS, March 23 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
KYGA MQBKY 500228 LNVGY UTX MCQEF KRYAF LKQ 0992 COL JSWSTEEL VTG LNVGF WYN KRYAY MQG

11
EU mergers and takeovers (March 21)

2018-03-21 reuters
BRUSSELS, March 21 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
KYGA MQBKY 500228 LNVGY YXOXY UTX MCQEF KRYAF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN KRYAY SSUMF MQG YXOXF

8
EU mergers and takeovers (March 20)

2018-03-20 reuters
BRUSSELS, March 20 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
MQBKY 500228 LNVGY YXOXY UTX MCQEF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN SSUMF MQG YXOXF

12
EU mergers and takeovers (March 16)

2018-03-16 reuters
BRUSSELS, March 16 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
MQBKY 500228 BBU LNVGY YXOXY UTX MCQEF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN SSUMF MQG YXOXF

12
EU mergers and takeovers (March 15)

2018-03-15 reuters
BRUSSELS, March 15 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
MQBKY 500228 BBU LNVGY YXOXY UTX MCQEF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN SSUMF MQG YXOXF

12
EU mergers and takeovers (March 14)

2018-03-14 reuters
BRUSSELS, March 14 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
MQBKY 500228 BBU LNVGY YXOXY UTX MCQEF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN SSUMF MQG YXOXF

12
EU mergers and takeovers (March 13)

2018-03-13 reuters
BRUSSELS, March 13 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
MQBKY 500228 BBU LNVGY YXOXY UTX MCQEF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN SSUMF MQG YXOXF

Related Articles

REPH: Recro Pharma Analysis and Research Report

20h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

21h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...